查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1968695

过敏诊断和治疗市场分析及预测（至2035年）：按类型、产品类型、服务、技术、应用、最终用户、设备、流程、安装类型和解决方案划分

Allergy Diagnostics & Therapeutics Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Device, Process, Installation Type, Solutions
出版日期: | 出版商: Global Insight Services | 英文 346 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计到2034年，过敏诊断和治疗市场规模将从2024年的332亿美元成长至607亿美元，复合年增长率约为6.2%。该市场涵盖旨在识别和治疗过敏性疾病的产品和服务，包括皮肤点刺试验和血清学检测等诊断测试，以及抗组织胺、皮质类固醇和免疫疗法等治疗药物。过敏症盛行率的上升和生物技术的进步正在推动市场成长。对个人化医疗和新型诊断技术的关注正在改善患者的治疗效果，并推动对过敏管理创新解决方案的需求。

受过敏症盛行率上升和诊断技术进步的推动，过敏诊断和治疗市场正经历强劲成长。诊断领域是成长的主要驱动力，其中，皮肤点刺试验等体内检测因其准确性和成本效益而被广泛采用。体外检测，特别是特异性IgE血液检测，因其非侵入性和不断扩大的临床应用范围而紧随其后。治疗方法也呈现显着成长，抗组织胺因其在控制过敏症状方面的有效性而成为成长最快的细分市场。免疫疗法，包括舌下和皮下给药，是成长第二快的细分市场，这得益于其在长期缓解症状和延缓疾病进展方面的潜力。个人化医疗方法的兴起，即根据个别患者情况量身定制治疗方案以改善治疗效果，正在推动市场持续扩张。生物製药和单株抗体的创新进一步提高了治疗效果，从而推动市场持续成长。更重视预防保健和病患教育也促进了市场动态。

市场区隔
类型 体内过敏诊断、体外过敏诊断、过敏治疗药物
产品 检测试剂盒、设备、耗材及试剂
服务 咨询、诊断和治疗服务
科技 酵素连结免疫吸附试验 (ELISA)、免疫检测、分子诊断、组成解析诊断 (CRD)
适应症 呼吸道过敏、食物过敏、药物过敏、皮肤过敏
最终用户 医院、诊断检查室、学术研究机构和专科诊所
装置 皮肤点刺试验装置、斑贴试验装置、血液检测装置
过程 检体采集、检体分析和结果解读
安装类型 携带式设备、固定式设备
解决方案 整合式过敏管理系统，独立诊断解决方案

市场概况：

过敏诊断和治疗市场的特点是众多市场参与企业竞相透过创新产品发布和策略定价来争夺竞争优势。市场占有率分散在成熟企业和新兴企业企业之间，这些企业都致力于提高诊断准确性和治疗效果。稳健的定价策略受到技术进步和新型诊断工具引入的影响。市场格局瞬息万变，各公司不断投资研发，推出尖端解决方案，以满足日益增长的过敏管理需求。竞争基准分析显示，主要参与者利用策略联盟和併购来巩固其市场地位，进而占据主导地位。监管影响至关重要，严格的指导方针塑造产品开发和核准流程。市场正经历着旨在扩大产品系列和地理覆盖范围的策略联盟激增。北美和欧洲的法规结构尤其具有影响力，它们在促进创新的同时，确保了产品的安全性和有效性。这种法规环境，加上技术进步，必将推动市场向前发展。

主要趋势和驱动因素：

由于过敏患者人数不断增加以及公众意识的提高，过敏诊断和治疗市场正经历强劲增长。关键趋势包括个人化医疗的进步，它能够根据个体的基因谱量身定制治疗方法，从而提高治疗效果。高通量筛检和次世代定序等技术创新显着提升了诊断能力，实现了过敏原的早期精准检测。另一个关键趋势是，人们对微创诊断方法的需求日益增长，这些方法能够提升患者的舒适度和便利性。环境变迁（包括污染和气候变迁）加剧了过敏症的发生率，并推动了市场需求。此外，新兴国家医疗基础设施的扩张也为市场准入开闢了新的途径。监管支持和研发投入的增加进一步促进了市场成长。投资于新型治疗方案（例如生物製药和免疫疗法）的公司有望获得竞争优势。随着全球对先进诊断和治疗方法的认知度和可及性的提高，该市场将持续扩张。

限制与挑战：

目前，过敏诊断和治疗市场面临许多重大限制和挑战。其中一项主要挑战是先进诊断技术的高成本。这一经济障碍限制了其可及性和广泛应用，尤其是在资源匮乏的地区。此外，医疗服务提供者和患者普遍缺乏对过敏诊断的认识和了解。这种知识鸿沟阻碍了市场渗透和成长。监管障碍也是重要的挑战。新诊断工具和治疗方法的严格核准流程延长了上市时间并增加了成本。此外，不同地区过敏盛行率的差异也限制市场发展。这种差异需要针对特定地区制定解决方案，并增加了诊断工具标准化和广泛应用的难度。最后，市场也面临物流方面的挑战，包括复杂的样本采集和运输。这些问题会导致延误和营运成本增加，进一步阻碍先进过敏诊断和治疗方法的应用。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 体内过敏诊断
    • 体外过敏诊断
    • 抗过敏药物
  • 市场规模及预测：依产品划分
    • 检测试剂盒
    • 装置
    • 消耗品
    • 试剂
  • 市场规模及预测：依服务划分
    • 咨询服务
    • 诊断服务
    • 治疗服务
  • 市场规模及预测：依技术划分
    • ELISA
    • 免疫检测
    • 分子诊断
    • CRD（组件解析诊断）
  • 市场规模及预测：依应用领域划分
    • 呼吸道过敏
    • 食物过敏
    • 药物过敏
    • 皮肤过敏
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊断实验室
    • 学术研究机构
    • 专科诊所
  • 市场规模及预测：依设备划分
    • 皮肤点刺试验装置
    • 贴片测试装置
    • 血液检测设备
  • 市场规模及预测：依製程划分
    • 检体采集
    • 样品分析
    • 结果解读
  • 市场规模及预测：依安装类型划分
    • 携带式装置
    • 固定设备
  • 市场规模及预测：按解决方案划分
    • 综合过敏管理系统
    • 独立诊断解决方案

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Stallergenes Greer
  • ALK-Abello
  • Anergis
  • Circassia Pharmaceuticals
  • Allergy Therapeutics
  • HAL Allergy Group
  • DBV Technologies
  • Leti Pharma
  • Abionic
  • Inmunotek
  • Diagenics
  • Omega Diagnostics
  • R-Biopharm
  • Biomerica
  • Bencard Allergie

第九章：关于我们

简介目录
Product Code: GIS33607

Allergy Diagnostics & Therapeutics Market is anticipated to expand from $33.2 billion in 2024 to $60.7 billion by 2034, growing at a CAGR of approximately 6.2%. The Allergy Diagnostics & Therapeutics Market encompasses products and services aimed at identifying and treating allergic conditions. This includes diagnostic tests like skin prick tests and serology, alongside therapeutics such as antihistamines, corticosteroids, and immunotherapy. Rising allergy prevalence and advancements in biotechnology are propelling market growth. Emphasis on personalized medicine and novel diagnostic technologies enhances patient outcomes, driving demand for innovative solutions in allergy management.

The Allergy Diagnostics & Therapeutics Market is experiencing robust growth, propelled by rising allergy prevalence and advancements in diagnostic technologies. The diagnostics segment leads in performance, with in vivo tests such as skin prick tests being widely employed due to their accuracy and cost-effectiveness. In vitro tests, particularly specific IgE blood tests, follow closely, driven by their non-invasive nature and expanding clinical applications. The therapeutics segment is also witnessing significant growth, with antihistamines being the top-performing sub-segment, owing to their efficacy in managing allergy symptoms. Immunotherapy, including sublingual and subcutaneous methods, is the second highest-performing sub-segment, reflecting its potential in providing long-term relief and modifying disease progression. Personalized medicine approaches are emerging, tailoring treatments to individual patient profiles and improving therapeutic outcomes. Innovations in biologics and monoclonal antibodies are further enhancing treatment efficacy, positioning the market for sustained expansion. The growing focus on preventive care and patient education is also contributing to market dynamics.

Market Segmentation
TypeIn Vivo Allergy Diagnostics, In Vitro Allergy Diagnostics, Allergy Therapeutics
ProductAssay Kits, Instruments, Consumables, Reagents
ServicesConsultation Services, Diagnostic Services, Therapeutic Services
TechnologyELISA, Immunoassay, Molecular Diagnostics, CRD (Component Resolved Diagnostics)
ApplicationRespiratory Allergies, Food Allergies, Drug Allergies, Skin Allergies
End UserHospitals, Diagnostic Laboratories, Academic Research Institutes, Specialty Clinics
DeviceSkin Prick Test Devices, Patch Test Devices, Blood Test Devices
ProcessSample Collection, Sample Analysis, Result Interpretation
Installation TypePortable Devices, Stationary Devices
SolutionsIntegrated Allergy Management Systems, Standalone Diagnostic Solutions

Market Snapshot:

The Allergy Diagnostics & Therapeutics Market is characterized by a diverse range of market participants, each vying for a competitive edge through innovative product launches and strategic pricing models. Market share is distributed among established players and emerging companies, with a focus on enhancing diagnostic accuracy and therapeutic efficacy. Robust pricing strategies are influenced by technological advancements and the introduction of novel diagnostic tools. The landscape is dynamic, with companies continuously investing in research and development to introduce cutting-edge solutions that cater to the growing demand for allergy management. Competition benchmarking reveals a landscape dominated by key players who are leveraging strategic partnerships and mergers to consolidate their market position. Regulatory influences play a pivotal role, with stringent guidelines shaping product development and approval processes. The market is witnessing a surge in strategic collaborations aimed at expanding product portfolios and geographic reach. Regulatory frameworks in North America and Europe are particularly influential, driving innovation and ensuring high standards of safety and efficacy. This regulatory environment, coupled with technological advancements, is poised to propel the market forward.

Geographical Overview:

The Allergy Diagnostics & Therapeutics Market is witnessing notable growth across various regions, each exhibiting unique characteristics. North America leads this expansion, driven by advanced healthcare infrastructure and a high prevalence of allergies. The region's focus on innovation and research further propels market growth. Europe follows closely, with strong government initiatives and rising awareness about allergies contributing to market expansion. In the Asia Pacific, rapid urbanization and increasing healthcare expenditure are significant growth drivers. Countries like China and India are emerging as lucrative markets due to their large populations and improving healthcare systems. Latin America and the Middle East & Africa are also showing promise as emerging markets. In Latin America, growing healthcare awareness and investments are spurring market growth. Meanwhile, the Middle East & Africa are recognizing the importance of allergy diagnostics and therapeutics in enhancing public health outcomes and addressing the rising allergy prevalence.

Key Trends and Drivers:

The Allergy Diagnostics & Therapeutics Market is experiencing robust growth due to rising allergy prevalence and increased awareness. Key trends include the advancement of personalized medicine, which tailors treatments to individual genetic profiles, enhancing effectiveness. Technological innovations, such as high-throughput screening and next-generation sequencing, are revolutionizing diagnostic capabilities, enabling earlier and more accurate detection of allergens. The growing demand for minimally invasive diagnostic procedures is another significant trend, offering patients greater comfort and convenience. Environmental changes, including pollution and climate change, are contributing to the heightened incidence of allergies, driving market demand. Moreover, the expansion of healthcare infrastructure in emerging economies is opening new avenues for market penetration. Regulatory support and increased investment in research and development are further propelling market growth. Companies investing in novel therapeutic solutions, such as biologics and immunotherapy, stand to gain a competitive edge. The market is set to expand as awareness and accessibility to advanced diagnostics and therapeutics increase globally.

Restraints and Challenges:

The Allergy Diagnostics & Therapeutics Market is currently navigating several significant restraints and challenges. A primary challenge is the high cost associated with advanced diagnostic technologies. This financial barrier limits accessibility and adoption, particularly in resource-constrained regions. Additionally, there is a pervasive lack of awareness and understanding about allergy diagnostics among both healthcare providers and patients. This knowledge gap hampers market penetration and growth. Regulatory hurdles also pose a significant challenge. Stringent approval processes for new diagnostic tools and treatments extend time-to-market and inflate costs. Moreover, the market is constrained by the variability in allergy prevalence across different regions. This variability necessitates localized solutions, complicating standardization and broad application of diagnostic tools. Finally, the market faces logistical challenges, including complexities in sample collection and transport. These issues can lead to delays and increased operational costs, further discouraging potential adoption of advanced allergy diagnostics and therapeutics.

Key Players:

Stallergenes Greer, ALK-Abell\o, Anergis, Circassia Pharmaceuticals, Allergy Therapeutics, HAL Allergy Group, DBV Technologies, Leti Pharma, Abionic, Inmunotek, Diagenics, Omega Diagnostics, R-Biopharm, Biomerica, Bencard Allergie

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Device
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Installation Type
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 In Vivo Allergy Diagnostics
    • 4.1.2 In Vitro Allergy Diagnostics
    • 4.1.3 Allergy Therapeutics
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Assay Kits
    • 4.2.2 Instruments
    • 4.2.3 Consumables
    • 4.2.4 Reagents
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consultation Services
    • 4.3.2 Diagnostic Services
    • 4.3.3 Therapeutic Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 ELISA
    • 4.4.2 Immunoassay
    • 4.4.3 Molecular Diagnostics
    • 4.4.4 CRD (Component Resolved Diagnostics)
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Respiratory Allergies
    • 4.5.2 Food Allergies
    • 4.5.3 Drug Allergies
    • 4.5.4 Skin Allergies
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Diagnostic Laboratories
    • 4.6.3 Academic Research Institutes
    • 4.6.4 Specialty Clinics
  • 4.7 Market Size & Forecast by Device (2020-2035)
    • 4.7.1 Skin Prick Test Devices
    • 4.7.2 Patch Test Devices
    • 4.7.3 Blood Test Devices
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Sample Collection
    • 4.8.2 Sample Analysis
    • 4.8.3 Result Interpretation
  • 4.9 Market Size & Forecast by Installation Type (2020-2035)
    • 4.9.1 Portable Devices
    • 4.9.2 Stationary Devices
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Integrated Allergy Management Systems
    • 4.10.2 Standalone Diagnostic Solutions

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Device
      • 5.2.1.8 Process
      • 5.2.1.9 Installation Type
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Device
      • 5.2.2.8 Process
      • 5.2.2.9 Installation Type
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Device
      • 5.2.3.8 Process
      • 5.2.3.9 Installation Type
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Device
      • 5.3.1.8 Process
      • 5.3.1.9 Installation Type
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Device
      • 5.3.2.8 Process
      • 5.3.2.9 Installation Type
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Device
      • 5.3.3.8 Process
      • 5.3.3.9 Installation Type
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Device
      • 5.4.1.8 Process
      • 5.4.1.9 Installation Type
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Device
      • 5.4.2.8 Process
      • 5.4.2.9 Installation Type
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Device
      • 5.4.3.8 Process
      • 5.4.3.9 Installation Type
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Device
      • 5.4.4.8 Process
      • 5.4.4.9 Installation Type
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Device
      • 5.4.5.8 Process
      • 5.4.5.9 Installation Type
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Device
      • 5.4.6.8 Process
      • 5.4.6.9 Installation Type
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Device
      • 5.4.7.8 Process
      • 5.4.7.9 Installation Type
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Device
      • 5.5.1.8 Process
      • 5.5.1.9 Installation Type
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Device
      • 5.5.2.8 Process
      • 5.5.2.9 Installation Type
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Device
      • 5.5.3.8 Process
      • 5.5.3.9 Installation Type
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Device
      • 5.5.4.8 Process
      • 5.5.4.9 Installation Type
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Device
      • 5.5.5.8 Process
      • 5.5.5.9 Installation Type
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Device
      • 5.5.6.8 Process
      • 5.5.6.9 Installation Type
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Device
      • 5.6.1.8 Process
      • 5.6.1.9 Installation Type
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Device
      • 5.6.2.8 Process
      • 5.6.2.9 Installation Type
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Device
      • 5.6.3.8 Process
      • 5.6.3.9 Installation Type
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Device
      • 5.6.4.8 Process
      • 5.6.4.9 Installation Type
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Device
      • 5.6.5.8 Process
      • 5.6.5.9 Installation Type
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Stallergenes Greer
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 ALK-Abello
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Anergis
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Circassia Pharmaceuticals
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Allergy Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 HAL Allergy Group
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 DBV Technologies
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Leti Pharma
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Abionic
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Inmunotek
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Diagenics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Omega Diagnostics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 R-Biopharm
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Biomerica
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Bencard Allergie
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us